Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
暂无分享,去创建一个
Thelma Thompson | David Fry | Kuo-Sen Huang | Mingxuan Xia | L. Vassilev | B. Graves | C. Lukacs | C. Janson | C. Garvie | Thelma O Thompson | C. Tovar | P. Di Lello | Jutta Wanner | D. Fry | A. Lovey | Christian Tovar | Lyubomir T Vassilev | Allen Lovey | Bradford Graves | Cheryl Janson | Christine Lukacs | Dayanand Deo | Paola Di Lello | Colin Garvie | Lin Gao | Jutta Wanner | Kuo-Sen Huang | D. Deo | Lin Gao | Mingxuan Xia
[1] M. Schutte,et al. Role of Mdm4 in drug sensitivity of breast cancer cells , 2010, Oncogene.
[2] D. Parks,et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo , 2006, Molecular Cancer Therapeutics.
[3] Christiane Riedinger,et al. Inhibitors of MDM2 and MDMX: a structural perspective. , 2009, Future medicinal chemistry.
[4] A. Jochemsen,et al. Functions of MDMX in the Modulation of the p53-Response , 2011, Journal of biomedicine & biotechnology.
[5] G. Wahl,et al. The p53 orchestra: Mdm2 and Mdmx set the tone. , 2010, Trends in cell biology.
[6] Jeremy R Stuart,et al. DNA Damage-induced MDMX Degradation Is Mediated by MDM2* , 2003, Journal of Biological Chemistry.
[7] T. Holak,et al. Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.
[8] Xuejun Jiang,et al. MdmX Protein Is Essential for Mdm2 Protein-mediated p53 Polyubiquitination , 2011, The Journal of Biological Chemistry.
[9] Mihee M. Kim,et al. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. , 2007, Cancer research.
[10] Jean-Christophe Marine,et al. Mdmx as an essential regulator of p53 activity. , 2005, Biochemical and biophysical research communications.
[11] M. Geiser,et al. Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes* , 2009, Journal of Biological Chemistry.
[12] J. Marine,et al. Mdm2-mediated ubiquitylation: p53 and beyond , 2010, Cell Death and Differentiation.
[13] A. Levine,et al. The p53 pathway: positive and negative feedback loops , 2005, Oncogene.
[14] Alan R. Fersht,et al. Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.
[15] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[16] G. Wahl,et al. Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry? , 2009, Molecular Cancer Research.
[17] O. Myklebost,et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[18] Shanghai Yu,et al. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. , 2009, Journal of medicinal chemistry.
[19] Yu Pan,et al. MDM2 Promotes Ubiquitination and Degradation of MDMX , 2003, Molecular and Cellular Biology.
[20] Dajun Yang,et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.
[21] T. Holak,et al. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain , 2008, Cell cycle.
[22] Baoying Huang,et al. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation , 2008, Cell cycle.
[23] Kristian Helin,et al. Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.
[24] L. Vassilev,et al. MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.
[25] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[26] D. Bashford,et al. Identification and Characterization of the First Small Molecule Inhibitor of MDMX* , 2010, The Journal of Biological Chemistry.
[27] L. Vassilev. p53 Activation by small molecules: application in oncology. , 2005, Journal of medicinal chemistry.
[28] S. Letteboer,et al. Hdmx Protein Stability Is Regulated by the Ubiquitin Ligase Activity of Mdm2* , 2003, Journal of Biological Chemistry.
[29] H. Kawai,et al. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo , 2011, Proceedings of the National Academy of Sciences.
[30] Chong Li,et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.
[31] Tina N. Davis,et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. , 2010, Cancer cell.
[32] G. Stark,et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. , 2006, Cancer research.
[33] D. Vaux,et al. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans , 2008, Cell Death and Differentiation.
[34] G. Wahl,et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 , 2006, Cell Death and Differentiation.
[35] G. Wahl,et al. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.
[36] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[37] Mengjia Tang,et al. Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells* , 2006, Journal of Biological Chemistry.